Schlap-1 ncRNA and uses thereof
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ncRNAs as diagnostic markers and clinical targets for prostate, lung, breast and pancreatic cancer.
1. A method comprising: (a) obtaining a sample from a subject having prostate cancer, wherein the sample comprises SChLAP-1; and (b) detecting the level of expression of SChLAP-1 in said sample.
2. The method of claim 1 , wherein the sample is selected from the group consisting of tissue, blood, plasma, serum, urine, urine supernatant, urine cell pellet, semen, prostatic secretions and prostate cells.
3. The method of claim 1 , wherein detection is carried out utilizing a method selected from the group consisting of a sequencing technique, a nucleic acid hybridization technique, a nucleic acid amplification technique, and an immunoassay.
4. The method of claim 3 , wherein the nucleic acid amplification technique is polymerase chain reaction, reverse transcription polymerase chain reaction, transcription-mediated amplification, ligase chain reaction, strand displacement amplification or nucleic acid sequence based amplification.
5. The method of claim 1 , wherein the subject has been diagnosed with localized prostate cancer or metastatic prostate cancer.
6. A method of treating a subject at risk of metastatic prostate cancer, said method comprising:
(a) obtaining or having obtained a level of expression of SChLAP-1 in a sample from a subject having prostate cancer, wherein the sample comprises non-coding RNAs (ncRNA);
(b) determining that the subject is at risk of developing metastatic prostate cancer when an increased level of expression of SChLAP-1 is detected; and
(c) administering a treatment comprising an effective amount of an anti-cancer therapeutic, a chemotherapy, radiation therapy, immunotherapy/biological therapy, or photodynamic therapy, to the subject determined to be at risk of developing metastatic prostate cancer based on said detection of an increased level of expression of SChLAP 1.
7. The method of claim 6 , wherein the anti-cancer therapeutic is a PARP inhibitor.
8. The method of claim 7 , wherein the PARP inhibitor is olaparib or ABT-888.
9. The method of claim 6 , wherein the sample is selected from the group consisting of tissue, blood, plasma, serum, urine, urine supernatant, urine cell pellet, semen, prostatic secretions and prostate cells.
10. The method of claim 6 , wherein the obtaining or having obtained the level of expression of SChLAP-1 comprises a method selected from the group consisting of a sequencing technique, a nucleic acid hybridization technique, a nucleic acid amplification technique, and an immunoassay.
11. The method of claim 1 , wherein the sample is a urine sample.
12. The method of claim 1 , wherein the sample is a prostate sample.
13. The method of claim 6 , wherein the sample is a urine sample.
14. The method of claim 6 , wherein the sample is a prostate sample.
15. The method of claim 6 , wherein the subject is determined to be at risk of developing metastatic prostate cancer based on detection of an increased level of expression of SChLAP-1, and wherein the subject determined to be at risk of developing metastatic prostate cancer is administered a treatment comprising an effective amount of an anti-cancer therapeutic, a chemotherapy, radiation therapy, immunotherapy/biological therapy, or photodynamic therapy.